.
VIRX financial statements
* Numbers in thousands
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
Capitalization * |
221 475 | 866 629 | 790 153 | 497 315 | 199 606 | 222 935 | 399 998 | 64 922 | 152 858 | 35 038 | 9 905 |
EV * |
221 617 | 875 950 | 793 075 | 484 386 | 180 554 | 229 314 | 380 225 | 58 622 | 145 562 | 14 628 | 14 628 |
Stock price $ |
286.316 | 1080 | 907.368 | 496.842 | 164.211 | 142.105 | 163.158 | 18.2456 | 17.5439 | 8.70175 | 2.46 |
Number of shares * |
774 | 802 | 871 | 1 001 | 1 216 | 1 569 | 2 452 | 3 558 | 8 713 | 4 027 | 4 027 |
EPS |
-26,04 | -54,77 | -39,73 | -42,96 | -30,17 | -24,24 | -14,46 | -7,48 | -2,68 | -5,37 | -5,37 |
Revenue * |
5 000 | 3 754 | 7 956 | 5 734 | 3 061 | 2 536 | 669 | 237 | 2 073 | 120 | 120 |
Net income * |
-20 141 | -43 951 | -34 598 | -43 002 | -36 676 | -38 023 | -35 458 | -26 615 | -23 330 | -21 610 | -21 610 |
Operating profit * |
-25 866 | -34 606 | -31 773 | -45 043 | -39 302 | -36 460 | -34 419 | -25 710 | -23 288 | -22 303 | -22 303 |
Total liabilities * |
17 849 | 61 060 | 46 709 | 30 444 | 19 609 | 22 210 | 12 790 | 11 331 | 9 697 | 3 310 | 3 310 |
Net debt * |
34 946 | 9 321 | 2 922 | -12 929 | -19 052 | 6 379 | -19 773 | -6 300 | -6 479 | -20 137 | -20 137 |
Total assets * |
45 869 | 73 017 | 40 525 | 44 246 | 47 002 | 43 234 | 34 334 | 15 324 | 37 240 | 23 247 | 23 247 |
Equity * |
28 020 | 11 957 | -6 184 | 13 802 | 27 393 | 21 024 | 21 544 | 3 993 | 27 543 | 19 937 | 19 937 |
Cash and investments * |
44 115 | 71 227 | 39 293 | 42 981 | 46 430 | 42 588 | 31 750 | 13 696 | 29 125 | 20 410 | 20 410 |
Over the past 10 years, the maximum capitalization of Viracta Therapeutics, Inc. is 866 629, the minimum is 35 038. Maximum net income 0, Minimum net income -43 951. The maximum price of VIRX shares is 1080, the minimum price is 8.70175.
.
VIRX valuation
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-11,00 | -19,72 | -22,84 | -11,56 | -5,44 | -5,86 | -11,28 | -2,44 | -6,55 | -1,62 | -0,46 |
P/B |
7,90 | 72,48 | -127,77 | 36,03 | 7,29 | 10,60 | 18,57 | 16,26 | 5,55 | 1,76 | 0,50 |
P/S |
44,30 | 230,86 | 99,32 | 86,73 | 65,21 | 87,91 | 597,90 | 273,93 | 73,74 | 291,99 | 82,54 |
E/P |
-9% | -5% | -4% | -9% | -18% | -17% | -9% | -41% | -15% | -62% | -218% |
P/FCF |
-9,69 | -81,43 | -21,11 | -11,50 | -5,15 | -6,03 | -11,06 | -2,66 | -6,89 | -1,63 | -0,46 |
.
VIRX profitability
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
ROE |
-72% | -368% | 559% | -312% | -134% | -181% | -165% | -667% | -85% | -108% | |
ROA |
-44% | -60% | -85% | -97% | -78% | -88% | -103% | -174% | -63% | -93% | |
ROIC |
-69% | -84% | -485% | -275% | -140% | -113% | -159% | -643% | -84% | -112% |